Oncimmune Hldngs PLC - Authorisation for EarlyCDT Lung in Brazil
ANVISA authorisation brings opportunity for EarlyCDT Lung sales in large Brazilian market
Lung cancer is the biggest cancer killer in
This marketing authorisation is effective immediately and enables market access for EarlyCDT Lung in one of the largest addressable markets in the world.
Dr Adam M Hill, CEO of
For further information:
+44 (0)20 3829 5000
finnCap (Joint Broker)
+44 (0)20 7220 0500
+44 (0)20 3727 1000
Our intimate understanding of the human immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies.
The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and give people extra time.
The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.
What is EarlyCDT Lung?
EarlyCDT is a simple blood test that detects the elevated presence of autoantibodies generated by the body's immune system as a natural defence against cancer cells.
EarlyCDT Lung is the world's most thoroughly validated blood test for the detection of lung cancer and requires only a small volume of blood which can be taken using a test in the home or community setting as well as a doctor's surgery. Shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis, EarlyCDT Lung can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
Quick facts: Oncimmune
Market Cap: £88.6 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE